Medications for Major Depressive Disorder

231 results

  • abilify

    (ARIPIPRAZOLE)
    Carilion Materials Management
    ABILIFY is indicated for treating schizophrenia, acute manic or mixed episodes in Bipolar I Disorder, adjunctive treatment of Major Depressive Disorder, irritability in autistic disorder, and Tourette’s disorder. The injectable form is used for agitation related to schizophrenia or bipolar mania.

  • abilify

    (ARIPIPRAZOLE)
    Rebel Distributors Corp.
    ABILIFY is indicated for the treatment of schizophrenia, bipolar I disorder (both monotherapy and adjunctive therapy), major depressive disorder as an adjunct to antidepressants, irritability associated with autistic disorder, and acute agitation related to schizophrenia or bipolar disorder.

  • abilify mycite

    (ARIPIPRAZOLE)
    Otsuka America Pharmaceutical, Inc.
    ABILIFY MYCITE is indicated for treating adults with schizophrenia, bipolar I disorder (including both acute and maintenance phases), and as adjunctive therapy for Major Depressive Disorder. It features an Ingestible Event Marker (IEM) sensor to track medication ingestion.

  • aplenzin

    (BUPROPION HYDROBROMIDE)
    STAT RX USA LLC
    Aplenzin™ (bupropion hydrobromide extended-release) is indicated for treating major depressive disorder, established through controlled trials. It helps maintain antidepressant response following initial treatment. Long-term use should be periodically reevaluated by the physician for individual patient benefit.

  • aripiprazole

    (Aripiprazole)
    Ascend Laboratories, LLC
    Aripiprazole Oral Tablets are indicated for treating schizophrenia, acute manic and mixed episodes of Bipolar I Disorder, as an adjunctive treatment for Major Depressive Disorder, irritability associated with autistic disorder, and Tourette’s disorder.

  • aripiprazole

    (ARIPIPRAZOLE)
    Accord Healthcare, Inc.
    Aripiprazole tablets are indicated for the treatment of schizophrenia, acute manic and mixed episodes in bipolar I disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and Tourette's disorder.

  • aripiprazole

    (Aripiprazole)
    Amneal Pharmaceuticals LLC
    Aripiprazole oral solution is indicated for treating schizophrenia, acute manic and mixed episodes in Bipolar I Disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and Tourette’s disorder.

  • bupropion

    (bupropion hydrochloride)
    Northwind Pharmaceuticals, LLC
    Bupropion hydrochloride extended-release (SR) tablets are approved for treating major depressive disorder (MDD) in adults. Efficacy was established in controlled trials, demonstrating effectiveness in both acute treatment and maintenance of antidepressant response for up to 44 weeks post-treatment.

  • bupropion

    (bupropion hydrochloride)
    NuCare Pharmaceuticals,Inc.
    Bupropion Hydrochloride Extended-release (SR) tablets are indicated for treating major depressive disorder (MDD). Efficacy was established in controlled trials, demonstrating effectiveness in both treating major depressive episodes and maintaining response after acute treatment.

  • bupropion hydrochloride

    (bupropion hydrochloride)
    Bryant Ranch Prepack
    Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD) and the prevention of seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Efficacy has been established through various controlled clinical trials.